Over the next six years, the purchase and production of biosimilar drugs can expect to see high double-digit growth. Are you familiar with the trends driving growth in the hottest market in therapeutic development?
CDISC standards are now mandatory. Your organization can either treat them as another regulatory weight, or use them to mitigate risk, drive down costs, and increase efficiency.
Biorasi is not just a contract research organization. We are Clinical Research Optimized™, which means that we achieve the ideal balance of cost, time and risk management. Through innovative project management processes and technologies, dedication to our sponsors, and a culture of ownership, our team will deliver to you on time, on budget, results every time.
The prevalence of Alzheimer’s disease (AD) is rapidly increasing as individual life spans across the world increase. It is currently the most common form of dementia, marked by the overproduction and aggregation of amyloid β (Aβ) and tau proteins in the brain. These...read more
For this week's Biorasi Spotlight, meet Mari Heghinian, PhD, Manager of Program Development at Biorasi, LLC. 1. How did you get into clinical research? After graduating with my PhD, I joined the pre-clinical group in a small Pharma company. The company...read more
If you had to pick one buzzword that perfectly encapsulated the current latest and greatest in innovation, you could do a lot worse than “big data”. The last few years have seen big data and data mining introduced into nearly every field imaginable, often with...read more